Clinical Study of Redirected Autologous T Cells With a Claudin18.2-targeted Chimeric Antigen Receptor in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs CAR-CLD18-T-cells-Carsgen-Therapeutics (Primary)
- Indications Adenocarcinoma; Gastric cancer; Pancreatic cancer
- Focus Adverse reactions
- 08 Mar 2018 Status changed from not yet recruiting to recruiting.
- 23 Jul 2017 Planned initiation date changed from 1 May 2017 to 1 Oct 2017.
- 24 May 2017 New trial record